Skip to main content
Lancet (London, England)
Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial - Authors' reply.
Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis.
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
Treatment of fibrotic interstitial lung disease: current approaches and future directions.
Pembrolizumab plus chemotherapy in triple-negative breast cancer - Authors' reply.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Multidrug-resistant tuberculosis - Authors' reply.
Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma.
